Check Out What Whales Are Doing With AMGN
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen. Looking at…
Expert Ratings For Amgen
In the latest quarter, 11 analysts provided ratings for Amgen (NASDAQ:AMGN), showcasing a mix of bullish and bearish…
Decoding Amgen’s Options Activity: What’s the Big Picture?
High-rolling investors have positioned themselves bullish on Amgen (NASDAQ:AMGN), and it’s important for retail traders to take note.…
Market Whales and Their Recent Bets on AMGN Options
Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN). And retail…
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key secondary endpoints were met with no new safety signals.
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca’s Drug
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.
What’s Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant ovarian cancer is underway.
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with higher blood eosinophil counts.
Reported Sunday, AstraZeneca And Amgen’s TEZSPIRE Shows Potential For Future Chronic Obstructive Pulmonary Diseasetreatment In New Data Presented At ATS 2024
Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE's impact on COPD exacerbations in patients with a broad range of eosinophil levels
The Phase IIa COURSE trial was a